Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
07/2000
07/27/2000CA2627837A1 Pharmaceutical compositions for alleviating discomfort
07/27/2000CA2361272A1 33 human secreted proteins
07/27/2000CA2361124A1 Vaccine-mediated treatment of neurological disorders
07/27/2000CA2361059A1 Piperidine, tetrahydropyridine and piperazine derivatives, their preparation and use
07/27/2000CA2359983A1 Phenylsulphonyl derivatives as 5-ht receptor ligands
07/27/2000CA2359680A1 Kinase inhibitors
07/27/2000CA2359572A1 Substituted 1-(piperidin-4-yl)-3-(aryl)-isothioureas, their preparation and therapeutic use
07/27/2000CA2359564A1 Method to aid smoking cessation
07/27/2000CA2359145A1 Exocytosis pathway proteins and methods of use
07/27/2000CA2359114A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2359113A1 Compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2359112A1 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2359105A1 New morpholinobenzamide salts
07/27/2000CA2359103A1 Substituted 1-(pieridin-4-yl)-3-(aryl) isothioureas their preparation and therapeutic application
07/27/2000CA2359096A1 Tripeptide compounds useful as selective inhibitors of aminopeptidase a and corresponding pharmaceutical compositions
07/27/2000CA2358914A1 Polypeptides derived from jnk3
07/27/2000CA2358584A1 Method of enhancing needleless transdermal powdered drug delivery
07/27/2000CA2358474A1 Pharmaceutical composition for the treatment of rheumatic syndromes containing sulfur, mustard seeds and a copper salt
07/27/2000CA2358093A1 Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4
07/27/2000CA2355168A1 Egg anti-inflammatory composition and method of treating and preventing inflammation
07/27/2000CA2353903A1 Fused heterocyclic compounds and their use in the treatment of neurodegenerative diseases
07/26/2000EP1022331A2 Transdifferentiation of transfected epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
07/26/2000EP1022330A2 Transdifferentiation of epidermal basal cells into neural progenitor cells, neuronal cells and/or glial cells
07/26/2000EP1022029A1 Nootropic agent
07/26/2000EP1021553A2 Eukaryotic gene expression cassette and uses thereof
07/26/2000EP1021549A2 SENSE mRNA THERAPY
07/26/2000EP1021540A1 Human progesterone receptor complex p23-like protein
07/26/2000EP1021533A1 Nucleic acids coding for proteins capable of interacting with presenilins
07/26/2000EP1021461A1 Use of neuronal and lymphocytic potassium canal inhibitors for treating neurological diseases of immune origin
07/26/2000EP1021446A1 Single pot process for producing (z)-azabicyclo oxime ethers
07/26/2000EP1021442A1 8-azabicyclo 3.2.1] octane-3-methanamine derivatives as ligands of d2 and d3 dopamine and 5ht1a and 5ht2 serotonin receptors
07/26/2000EP1021440A2 Antipsychotic substituted piperidine derivatives
07/26/2000EP1021434A2 Pharmacologically active compounds and use
07/26/2000EP1021432A1 Halogen substituted tetracyclic tetrahydrofuran derivatives
07/26/2000EP1021430A1 Furan nitrone compounds
07/26/2000EP1021425A1 N-aminoalkyl-2-anthraquinonecarboxamides; dopamine receptor subtype specific ligands
07/26/2000EP1021418A1 Substituted 2,3-benzodiazepin-4-ones and the use thereof
07/26/2000EP1021415A1 Tricyclic aminoalkylcarboxamides; novel dopamine d 3? receptor subtype specific ligands
07/26/2000EP1021413A1 The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
07/26/2000EP1021199A1 PEPTIDE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS
07/26/2000EP1021193A1 THERAPEUTICALLY EFFECTIVE 1$g(a), 25-DIHYDROXYVITAMIN D 3? ANALOGS
07/26/2000EP1021186A1 PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha
07/26/2000EP1021185A1 Didhydropyrimidines and uses thereof
07/26/2000EP1021183A1 A COMBINATION OF A SELECTIVE 5-HT 1A? ANTAGONIST AND A SELECTIVE h5-HT 1B? ANTAGONIST OR PARTIAL AGONIST
07/26/2000EP1021175A1 Compounds and methods for therapeutic intervention in preventing diabetic complications
07/26/2000EP1021174A2 Medicaments
07/26/2000EP1021087A1 Serotonin containing formulation for oral administration and method of use
07/26/2000EP0827503B1 Pyrrolidinyl methyl indole salt
07/26/2000EP0736011B1 Anellated dihydropyridines and their use in the production of pharmaceutical preparations
07/26/2000CN1261361A 5-(2-Ethyl-2H-tetrazol-5-Y1)-1-methyl-1,2,3,6-tetrahydropyridine maleate
07/26/2000CN1261352A New 'beta'-amino and 'beta'-azidocarboxylic acid derivatives, the production thereof and the use thereof as endothelin receptor an tagonists
07/26/2000CN1261350A Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
07/26/2000CN1261279A Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
07/26/2000CN1261277A Novel substituted imidazole compounds
07/26/2000CN1261274A Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them.
07/26/2000CN1261273A Delayed-release dosage forms of sertraline
07/26/2000CN1261073A Tricyclooxime ethers, preparations thereof and medicinal compositions containing them
07/26/2000CN1054856C New 19-nor steroids having phenoxyalkylsulphonemide or phenoxyalkylsulphonylurea chain in position llbeta, preparation process and intermediates, use as medicaments and pharmaceutical
07/26/2000CN1054850C Piperazine compounds used in therapy
07/26/2000CN1054848C New benzopyran derivatives, their process of preparation and pharmaceutical compositions
07/26/2000CN1054844C N-substituted azabicycloheptane derivatives, their preparation and use
07/26/2000CN1054766C Oral liquor for curing and regulating heart spleen and kidney functions
07/26/2000CN1054762C Medicine for treatment of eqilepsy
07/26/2000CN1054761C Medicine for abstaining from drugs and its preparation
07/25/2000US6093822 5-arylindole derivatives
07/25/2000US6093820 Reacting an imide with a (substituted)alkoxyalkylsulfonic acid ester to form a n-alkoxyalkyl imide such as methoxymethyl ethosuximide; administering as anticonvulsant, antianxiety agent and muscle relaxant
07/25/2000US6093802 Culturing cells transformed to express a nerve growth factor of specific amino acid sequence, activity, or weight and isolating protein; for treatment of alzheimer's/parkinson's diseases, amyotrophic lateral sclerosis, and nerve damage
07/25/2000US6093797 Modifications of the tripeptide hormone melanocyte stimulating inhibitory factor; can cross blood-brain barrier; side effect reduction
07/25/2000US6093747 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivatives as anxiolytic agents having enhanced receptor specificity
07/25/2000US6093743 Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
07/25/2000US6093733 Muscarinic receptor agonists
07/25/2000US6093724 Muscarinic agonists and antagonists
07/25/2000US6093720 An antioxidant, antiischemic as well as antiamnesic effects for inhibiting lipid peroxidation, treating various degenerative neurological diseases alzheimer's disease
07/25/2000US6093713 A tyrosine kinase inhibitor for enhancing the function of a cholinergic neuron
07/25/2000US6093703 Pharmaceutical compositions, containing S-adenosyl-L-methionine salt, 5-methyl-tetrahydrofolic acid and 5-formyltetrahydrofolic acid
07/25/2000US6093561 Human lysophospholipase
07/25/2000US6093390 Methods for promoting functional regeneration of mammalian muscle by administering leukaemia inhibitor factor
07/25/2000CA2197086C (azetidin-1-ylalkyl)lactams as tachykinin antagonists
07/25/2000CA2169115C 1-¬2-(substituted vinyl)|-5h-2,3-benzodiazepine derivatives
07/25/2000CA2167688C Methods and compositions for inhibiting uridine secretion
07/20/2000WO2000042202A1 A method for introducing substances into cells, and use of said method
07/20/2000WO2000042191A2 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
07/20/2000WO2000042179A2 Complex-forming proteins
07/20/2000WO2000042172A2 Human homologues of proteins regulated by circadian rhythms
07/20/2000WO2000042074A1 Anti-ccr4 antibodies and methods of use therefor
07/20/2000WO2000042054A1 2,3-o-isopropylidene derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000WO2000042053A1 Derivatives of monosaccharides as cell adhesion inhibitors
07/20/2000WO2000042044A1 Novel aralkyl amines of spirofuropyridines useful in therapy
07/20/2000WO2000042042A2 High affinity inhibitors for target validation and uses thereof
07/20/2000WO2000042040A1 Tricyclic inhibitors of poly(adp-ribose) polymerases
07/20/2000WO2000042038A1 Triazole compounds with dopamine-d3-receptor affinity
07/20/2000WO2000042037A1 Triazole compounds with dopamine-d3-receptor affinity
07/20/2000WO2000042036A1 Triazole compounds with dopamine-d3-receptor affinity
07/20/2000WO2000042035A1 4-(heterocyclylsulfonamido) -5-methoxy-6- (2-methoxyphenoxy) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
07/20/2000WO2000042031A2 Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
07/20/2000WO2000042029A1 1-heterocycle substituted diarylamines
07/20/2000WO2000042027A1 Novel polyhydroxypyrazine derivatives, preparation and pharmaceutical compositions containing same
07/20/2000WO2000042025A1 Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
07/20/2000WO2000042023A1 Substituted imidazoles, their preparation and use
07/20/2000WO2000042022A1 Benzoheterocycles and their use as mek inhibitors
1 ... 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 ... 1833